Cargando…

Efficacy and safety of EGFR‑TKIs plus Shenqi Fuzheng injection for non-small cell lung cancer patients with EGFR-sensitive mutations

PURPOSE: The aim of this retrospective study is to evaluate the impact on efficacy and safety between epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) alone and in combination with Shenqi Fuzheng injection (SFI) in patients with advanced NSCLC harboring epidermal growth factor...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wang, Jia-li, Chen, Chuan-sheng, Jia, Zhi-rong, Miao, Li-yun, Xie, Jun, Pan, Zhen-zhen, Duan, Ya-lei, Liu, Shuo, Hou, Meng-jun, Ding, Xuan-sheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Berlin Heidelberg 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10314878/ https://www.ncbi.nlm.nih.gov/pubmed/36008690 http://dx.doi.org/10.1007/s00432-022-04297-3

Ejemplares similares

Neuroprotective effect of Shenqi Fuzheng injection pretreatment in aged rats with cerebral ischemia/reperfusion injury
por: Cai, Ying-min, et al.
Publicado: (2016)

Shenqi Fuzheng Injection Combined With Chemotherapy for Gastric Cancer: An Overview of Systematic Reviews and Meta-Analyses
por: Xu, Jing, et al.
Publicado: (2023)

Clinical efficacy and safety of Shenqi Fuzheng injection for the treatment of chronic heart failure: Protocol for a meta-analysis and systematic review
por: Wang, Chuan, et al.
Publicado: (2019)

ShenQi FuZheng Injection combined with chemotherapy in the treatment of colorectal cancer: A meta-analysis
por: Xu, Rongzhong, et al.
Publicado: (2017)

Neuroprotective Effects of Shenqi Fuzheng Injection in a Transgenic SOD1-G93A Mouse Model of Amyotrophic Lateral Sclerosis
por: Sugimoto, Kazuo, et al.
Publicado: (2021)

Shenqi Fuzheng Injection impairs bile duct ligation-induced cholestatic liver injury in vivo
por: Cao, Fei, et al.
Publicado: (2019)

Shenqi Fuzheng Injection in the Treatment of Breast Cancer: A Meta-analysis of Randomized Controlled Trials
por: Liu, Shuyu, et al.
Publicado: (2018)

Systems assessment of intercalated combination of chemotherapy and EGFR TKIs versus chemotherapy or EGFR TKIs alone in advanced NSCLC patients
por: Yan, Han, et al.
Publicado: (2015)

Combination of EGFR-TKIs with chemotherapy versus chemotherapy or EGFR-TKIs alone in advanced NSCLC patients with EGFR mutation
por: Wen, Miaomiao, et al.
Publicado: (2018)

Shenqi Fuzheng Injection Combined with Chemotherapy for Breast Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Lv, Yanhong, et al.
Publicado: (2015)

Shenqi Fuzheng Injection Alleviates the Transient Worsening Caused by Steroids Pulse Therapy in Treating Myasthenia Gravis
por: Qi, Guo-Yan, et al.
Publicado: (2013)

Immunoregulation of Shenqi Fuzheng Injection Combined with Chemotherapy in Cancer Patients: A Systematic Review and Meta-Analysis
por: Yang, Yang, et al.
Publicado: (2017)

Microwave ablation combined with EGFR-TKIs versus only EGFR-TKIs in advanced NSCLC patients with EGFR-sensitive mutations
por: Wei, Zhigang, et al.
Publicado: (2017)

Shenqi Fuzheng Injection (SFI) Enhances IFN-α Inhibitory Effect on Hepatocellular Carcinoma Cells by Reducing VEGF Expression: Validation by Gene Silencing Technique
por: Chen, Xiaoheng, et al.
Publicado: (2019)

Erratum to “Shenqi Fuzheng Injection Alleviates the Transient Worsening Caused by Steroids Pulse Therapy in Treating Myasthenia Gravis”
por: Qi, Guo-Yan, et al.
Publicado: (2014)

ShenQi FuZheng injection as an adjunctive treatment to chemotherapy in breast cancer patients: a meta-analysis
por: Zhang, Hongbo, et al.
Publicado: (2019)

Estimation of cell-free circulating EGFR mutation concentration predicts outcomes in NSCLC patients treated with EGFR-TKIs
por: Zhu, Yan-juan, et al.
Publicado: (2017)

Phosphorylated EGFR expression may predict outcome of EGFR-TKIs therapy for the advanced NSCLC patients with wild-type EGFR
por: Wang, Fen, et al.
Publicado: (2012)

Effect of Shenqi Fuzheng Injection on Leukopenia and T-cell Subsets in Patients with Non-small Cell Lung Cancer Undergoing Radiotherapy
por: Wu, Chengde, et al.
Publicado: (2022)

Shenqi Fuzheng injection reverses M2 macrophage-mediated cisplatin resistance through the PI3K pathway in breast cancer
por: Yan, Bin, et al.
Publicado: (2023)

EGFR-TKIs resistance via EGFR-independent signaling pathways
por: Liu, Qian, et al.
Publicado: (2018)

Phosphorylated STYK1 restrains the inhibitory role of EGFR in autophagy initiation and EGFR-TKIs sensitivity
por: Zhou, Cefan, et al.
Publicado: (2022)

The Clinical Outcomes of Different First-Line EGFR-TKIs Plus Bevacizumab in Advanced EGFR-Mutant Lung Adenocarcinoma
por: Huang, Yen-Hsiang, et al.
Publicado: (2022)

Efficacy observation and prognosis analysis of EGFR-TKIs alone versus EGFR-TKIs plus chemotherapy in advanced lung adenocarcinoma with EGFR Exon 19 Deletion, Exon 21 L858R mutation: A historical cohort study
por: Zhou, Jinhua, et al.
Publicado: (2023)

The peripheral blood neutrophil-to-lymphocyte ratio is a prognostic predictor for survival of EGFR-mutant nonsmall cell lung cancer patients treated with EGFR-TKIs
por: Zhang, Yuan, et al.
Publicado: (2018)

Combination TS‐1 plus EGFR‐tyrosine kinase inhibitors (TKIs) for the treatment of non‐small cell lung cancer after progression on first‐line or further EGFR‐TKIs: A phase II, single‐arm trial
por: Yang, Lu, et al.
Publicado: (2018)

Osimertinib or EGFR-TKIs/chemotherapy in patients with EGFR-mutated advanced nonsmall cell lung cancer: A meta-analysis
por: Huang, Lei, et al.
Publicado: (2019)

Bisphosphonates enhance EGFR-TKIs efficacy in advanced NSCLC patients with EGFR activating mutation: A retrospective study
por: Huang, Chu-Ying, et al.
Publicado: (2015)

Shenqi fuzheng, an injection concocted from chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review
por: Dong, Ju, et al.
Publicado: (2010)

Clinical outcomes of WBRT plus EGFR-TKIs versus WBRT or TKIs alone for the treatment of cerebral metastatic NSCLC patients: a meta-analysis
por: Zheng, Hong, et al.
Publicado: (2017)

Pulmonary pleomorphic carcinoma: A case harboring EGFR mutation treated with EGFR‐TKIs
por: Masuda, Ken, et al.
Publicado: (2018)

Authentication of Shenqi Fuzheng Injection via UPLC-Coupled Ion Mobility—Mass Spectrometry and Chemometrics with Kendrick Mass Defect Filter Data Mining
por: Wu, Xingdong, et al.
Publicado: (2022)

Shenqi Fuzheng Injection Reverses Cisplatin Resistance through Mitofusin-2-Mediated Cell Cycle Arrest and Apoptosis in A549/DDP Cells
por: Xiong, Ying, et al.
Publicado: (2018)

The influence of tumor heterogeneity on sensitivity of EGFR-mutant lung adenocarcinoma cells to EGFR-TKIs
por: Sun, Li, et al.
Publicado: (2019)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in EGFR-Mutant Stage III-pN2 Lung Adenocarcinoma
por: Li, Qiwen, et al.
Publicado: (2021)

Evaluating the Efficacy of EGFR-TKIs Combined With Radiotherapy in Advanced Lung Adenocarcinoma Patients With EGFR Mutation: A Retrospective Study
por: Wang, Yuxiang, et al.
Publicado: (2022)

Influence of PD‐L1 expression on the efficacy of EGFR‐TKIs in EGFR ‐mutant non‐small cell lung cancer
por: Lei, Si‐Yu, et al.
Publicado: (2023)

Prognostic value of plasma EGFR ctDNA in NSCLC patients treated with EGFR-TKIs
por: Zhang, Chengjuan, et al.
Publicado: (2017)

PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs
por: Bai, Yuchen, et al.
Publicado: (2018)

Serum proteomic study on EGFR-TKIs target treatment for patients with NSCLC
por: Wu, Xuan, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_2o7u399limjjkmfa8hsr2lr2g1